A new antiviral facemask which uses nanotechnology to kill viruses including COVID-19 and influenza has been designed and developed by scientists at Pharm2Farm Ltd and Nottingham Trent University.
Instead of the usual three-ply design, the five-ply surgical mask includes an additional antiviral inner layer which incorporates Pharm2Farm’s patented anti pathogenic nanotechnology (GB 2016813.4, 22 October 2020).
On contact with the virus, Pharm2Farms proprietary nanotechnology, which is embedded into the mask material, emits ions that penetrate through the surface envelope of the virus and of destroy the genetic material causing it to die and stop reproducing. The nanotech has a large surface area making the approach more effective at killing the virus without reducing the breathability of the mask. The antiviral inner layer ensures additional protection for both the wearer and those in proximity.
Pharm2farm uses a patented process for producing and functionalising nanoparticles for various applications including human, animal and crop health. Pharm2farm is a wholly owned subsidiary of Remote Monitored Systems (LON:RMS).
